JP Morgan Downgrades AMAG Pharmaceuticals to Underweight

by Juan Lopez, Benzinga Staff Writer

January 23, 2012 7:52 AM | 8 seconds read | Make a Comment

JP Morgan has downgraded AMAG Pharmaceuticals

AMAG

from Neutral to Underweight and has lowered the price target from $20 to $12.

Posted In: Downgrades Price Target Pre-Market Outlook Analyst Ratings JP Morgan

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.